NURSING DOMAIN
Published July 11, 2023 | Version v1
Journal article Open

Causes, Symptoms, Intellectual Disability, Behavioural Issues, Skin Conditions, Microcephaly, Seizures, Management, Regular Monitoring, Nutrition a Supplementation, Support As Well As Counselling of Classical PKD and Symptoms, Treatment As Well As Management, Future Perspectives Of Non Classical PKD and Genetic Basis As Well As Management Strategies, Psychosocial Impact, Diagnosis As Well As Treatment of Variant Forms of PKU

Authors/Creators

  • 1. Veterinay Doctor, College of veterinary science, Proddatur, Andhra Pradesh, India
  • 2. Associate Professor, College of veterinary science, Proddatur, Andhra Pradesh, India
  • 3. Staff, Indian Veterinary Research Institute (IVRI), Izathnagar, Barielly district, Uttar Pradesh, India
  • 4. Assistant Professor, College of Veterinary Science, Korutla, PVNRTVU, Telengana, Hyderabad, India
  • 5. Assistant General Manager, Vaishnavi Bio pharma pvt. Ltd., Telanagana, India
  • 6. Assistant Professor, Contract Teaching Faculty, College of veterinary, science, Proddatur, Andhra Pradesh, India

Description

Phenylketonuria (PKU) is a genetic disorder with an incidence of approximately 1 in 10,000 to 15,000 births worldwide. Phenylketonuria is an inherited metabolic disorder manifested by the lack of ability to metabolize phenylalanine, an amino acid found in many protein-rich foods. This review provides a detailed overview of PKU, including its types, clinical manifestations, and management strategies. The understanding of PKU has developed over the years, leading to improved diagnosis and treatment approaches. Early detection and intervention play a crucial role in obstructing intellectual disabilities and ensuring a better quality of life for individuals with PKU.

 

Files

CAUSES, SYMPTOMS, INTELLECTUA DISABILITY (1).pdf

Files (193.9 kB)

Name Size
md5:df7f5fd84e292cf0a37673f09d5ff01a
193.9 kB Preview Download

Additional details

References

  • 1. Williams, R. A., Mamotte, C. D., & Burnett, J. R. (2008). Phenylketonuria: an inborn error of phenylalanine metabolism. The Clinical Biochemist Reviews, 29(1), 31.
  • 2. Flydal, M. I., & Martinez, A. (2013). Phenylalanine hydroxylase: function, structure, and regulation. IUBMB life, 65(4), 341-349.
  • 3. Michals-Matalon, K., Bhatia, G., Guttler, F., Tyring, S. K., & Matalon, R. (2007). Response of phenylketonuria to tetrahydrobiopterin. The Journal of nutrition, 137(6), 1564S-1567S.
  • 4. Christ, S. E., Moffitt, A. J., Peck, D., & White, D. A. (2013). The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria. NeuroImage: Clinical, 3, 539-547.
  • 5. Prick, B. W., Hop, W. C., & Duvekot, J. J. (2012). Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies. The American journal of clinical nutrition, 95(2), 374-382.
  • 6. Chandler, R. J., & Venditti, C. P. Gene therapy for metabolic diseases. Transl Sci Rare Dis. 2016; 1 (1): 73–89.
  • 7. Hofman, D. L., Champ, C. L., Lawton, C. L., Henderson, M., & Dye, L. (2018). A systematic review of cognitive functioning in early treated adults with phenylketonuria. Orphanet journal of rare diseases, 13, 1-19.